CN106279305A - Amide alkaloid compound and extraction separation method thereof in Herba Portulacae - Google Patents

Amide alkaloid compound and extraction separation method thereof in Herba Portulacae Download PDF

Info

Publication number
CN106279305A
CN106279305A CN201610663629.3A CN201610663629A CN106279305A CN 106279305 A CN106279305 A CN 106279305A CN 201610663629 A CN201610663629 A CN 201610663629A CN 106279305 A CN106279305 A CN 106279305A
Authority
CN
China
Prior art keywords
compound
alkaloid compound
separation method
amide alkaloid
herba portulacae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610663629.3A
Other languages
Chinese (zh)
Other versions
CN106279305B (en
Inventor
英锡相
英哲铭
徐靓
张文洁
张朝绅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liaoning University of Traditional Chinese Medicine
Original Assignee
Liaoning University of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liaoning University of Traditional Chinese Medicine filed Critical Liaoning University of Traditional Chinese Medicine
Priority to CN201610663629.3A priority Critical patent/CN106279305B/en
Publication of CN106279305A publication Critical patent/CN106279305A/en
Application granted granted Critical
Publication of CN106279305B publication Critical patent/CN106279305B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to Chinese medicine extraction, separation field, particularly relate to extracting and developing and the special amide alkaloid compound identified and extraction separation method thereof from Herba Portulacae.Described new alkaloids compound, molecule formula successively is C24H39NO7, named oleraciamide C.Also provide for the extraction separation method of above-mentioned new alkaloids compound, use 50% alcohol reflux successively, macroporous adsorption resin chromatography, ethyl acetate extracts, polyamide column chromatography, silica gel column chromatography, Sephadex LH 20 purification, in ODS, compression leg is isolated and purified, successfully extract and isolate a kind of new special amide alkaloid compound, amide alkaloid compound has antiinflammatory, antitumor and neuroprotective, amide alkaloid compound of the present invention and salt or derivant thereof can be as other compou nd synthesis primers, and new drug development and the raw material of pharmacology activity research, for preparing antiinflammatory, antitumor and the medicine of neuroprotective or health product.

Description

Amide alkaloid compound and extraction separation method thereof in Herba Portulacae
Technical field
The present invention relates to Chinese medicine extraction, separation field, particularly relate to from purslane medicinal material extracting and developing and identify Amide alkaloid and extraction separation method thereof.
Background technology
Herba Portulacae (Portulaca oleracea L.), has another name called long life dish, horse Amaranthus mangostanus L., for portulacaceous plant.Herba Portulacae Drought-enduring waterlogging, and fast light resistance to the moon, widely distributed, aboundresources, the wild plant as medicine-food two-purpose receives much concern, 2015 editions The dry aerial parts recording Herba Portulacae in the Pharmacopoeia of the People's Republic of China are used as medicine, and have heat-clearing and toxic substances removing, cooling blood for hemostasis, dysentery relieving Etc. effect, for toxic-heat and blood stasis, carbuncle furuncle, eczema, erysipelas, snake bite and insect sting, have blood in stool, hemorrhoidal bleeding, metrostaxis etc..
The research of Herba Portulacae modern pharmacology shows, it has anti-inflammatory analgesic, anti-bacteria and anti-virus, lowering blood pressure and blood fat, antioxygen Change, anticancer, relax skeletal muscle and the effect such as smooth muscle, regulation immunologic function.Research shows that the numerous chemical composition of Herba Portulacae is it Various pharmacological action provides material base, and Herba Portulacae main chemical compositions includes flavonoid, coumarin, terpenoid, steroid, life Alkaloids, aminoacid, various pigment and minerals etc..The chemical composition that during wherein alkaloid is Herba Portulacae, a class is main, mesh Before the alkaloids composition reported have norepinephrine, dopamine, a small amount of DOPA, adenosine, uracil, adenine, N, N- 1,3-Dicyclohexylurea, allantoin, N-be trans-Resina Ferulae acyl group tyramine；Also Cyclic dipeptides alkaloid and amide alkaloid: Herba Portulacae acyl Amine A-I, K, L, N-S.
From Herba Portulacae, isolated chemical composition great majority are known at present, and novel structure is relatively low, therefore, right In Herba Portulacae, exploitation and the separation of noval chemical compound urgently need.
Summary of the invention
For the problems referred to above, the present invention provides the one special amide alkaloid compound extracted from Herba Portulacae, warp Research finds that the special alkaloid of the present invention has the effect of antiinflammatory, antitumor, neuroprotective, provides a kind of for this simultaneously The simplicity of bright new alkaloids compound, quickly, environmental protection, extraction separation method that purity is high.
For realizing the above-mentioned purpose of the present invention, the amide alkaloid compound that the present invention provides, molecular formula is C24H39NO7, named oleraciamide C.Chemical structural formula is:
For realizing the above-mentioned purpose of the present invention, the present invention also provides for special amide alkaloid compound in a kind of Herba Portulacae Extraction separation method, concretely comprise the following steps.
Step 1, take Herba Portulacae and be dried medical material, use 50% alcohol reflux, decompression recycling ethanol, cool to room temperature, Obtain medicinal liquid standby.
Step 2, step 1 herb liquid uses the method for static adsorption by AB-8 type macroporous resin, uses water successively, 50%, 70% ethanol gradient elution, repeatedly extract by ethyl acetate after 70% alcohol elution concentrating under reduced pressure, recovered under reduced pressure Ethyl acetate, to extractum, obtains acetic acid ethyl ester extract.
Step 3, by acetic acid ethyl ester extract in step 2 through polyamide column separate, use alcohol-water gradient elution, 70% Ethanolic moiety is upper silicagel column after being evaporated, and obtains some eluting positions, through thin layer chromatography with acetate-methanol gradient elution successively Detecting, colour developing, merge the eluting position of colour developing, the eluting position after merging is done through being evaporated to, standby.
Step 4, by gains in step 3 again through Sephadex LH-20 (hydroxypropyl polydextran gel) process, with methanol- Water isocratic elution, obtains some eluting positions, detects through thin layer chromatography, colour developing, merges the eluting position of colour developing, will merge After eluting position do through being evaporated to, standby.
Step 5, by gained concentrate pretreated ODS post (Octadecylsilyl, octadecylsilane in step 4 Bonded silica gel filler) chromatography, the amide alkaloid compound deriving from Herba Portulacae is afforded with methanol-water.It is pure Spend through high performance liquid chromatography detection higher than 98%.
The preprocessing process of described ODS and Sephadex LH-20 gel is that methanol soaked 24 hours, and upper prop uses methanol It is washed till without muddy in instillation water, then balances each other with initial flow.
Compared with prior art beneficial effects of the present invention.
Separation and the pharmacology activity research of heretofore described Herba Portulacae special amide alkaloid compound are the most existing Paper periodical is reported；The present invention provides and derives from the special amide alkaloid compound of Herba Portulacae and one for the present invention The extraction separation method of noval chemical compound, uses 50% alcohol reflux, macroporous adsorption resin chromatography, ethyl acetate to extract successively Take, compression leg is isolated and purified in polyamide column chromatography, silica gel column chromatography, Sephadex LH-20 purification, ODS, successfully extracts separation Going out a kind of amide alkaloid compound, the method operating procedure is only five steps, and operational approach is easy and quick, extracts and separated Journey mainly uses 50% ethanol extraction and ethyl acetate to extract, process environmental protection, and through the compound of the method isolated Purity is higher is all higher than 90%, shows that this compound has antiinflammatory, antitumor and neuroprotective, therefore originally the most after deliberation The one special amide alkaloid compound of invention and salt and derivant can as other compou nd synthesis primers, with And new drug development and the raw material of pharmacology activity research, also can be used for preparing the medicine of antiinflammatory, antitumor and neuroprotective.
Accompanying drawing explanation
Fig. 1 is the ultraviolet spectrogram of amide alkaloid compound oleraciamide C of the present invention.
Fig. 2 is the infrared spectrogram of amide alkaloid compound oleraciamide C of the present invention.
Fig. 3 is amide alkaloid compound oleraciamide C of the present invention1H-NMR spectrogram.
Fig. 4 is amide alkaloid compound oleraciamide C of the present invention13C-NMR spectrogram.
Fig. 5 is carbon-13 nmr spectra (DEPT) spectrum of amide alkaloid compound oleraciamide C of the present invention Figure.
Fig. 6 is the nuclear magnetic resonance, NMR of amide alkaloid compound oleraciamide C of the present invention1H-1HCOSY spectrogram.
Fig. 7 is the nuclear magnetic resonance, NMR HMBC spectrogram of amide alkaloid compound oleraciamide C of the present invention.
Fig. 8 is the nuclear magnetic resonance, NMR HSQC spectrogram of amide alkaloid compound oleraciamide C of the present invention.
Fig. 9 is the nuclear magnetic resonance, NMR NOESY spectrogram of amide alkaloid compound oleraciamide C of the present invention.
Detailed description of the invention
Embodiment 1.
The present invention provides a kind of special amide alkaloid compound, and molecular formula is C24H39NO7, named Oleraciamide C, chemical structural formula is:
Described special amide alkaloid compound is this alkaloid according to structure named oleraciamide C, table 1 The nuclear magnetic data of compound:1H-NMR with13C-NMR is in deuterated methanol.
Table 1: the nuclear magnetic data of new alkaloids compound of the present invention
Refer to Fig. 1-9, the Structural Identification of the present invention special amide alkaloid compound and derivation.
Oleraciamide C: white oil thing, is soluble in methanol, insoluble, be slightly soluble in water.Point sample is in silica gel thin-layer plate After, spray dilute bismuth potassium iodide test solution speckle and show orange, pointing out this compound is alkaloid component, and Molish reacts the explanationization that is positive Containing glycosyl in compound.UV(MeOH)λmax: 205,219,269nm, IR νN-H3409cm-1, ν=CH3012cm-1, νCH2928cm-1, 2856cm-1νC=O1737cm-1, δCH 1384cm-1, νC-N1168cm-1, νC-O1075cm-1.HRESI (+) TOFMS provides m/z: 454.2876[M+H]+Quasi-molecular ion peak, molecular weight is 453.5801.In conjunction with1H-NMR,13C-NMR and DEPT data, Speculate that the possible molecular formula of this compound is C24H39NO7, degree of unsaturation is 6.13C-NMR spectrum and 24 carbon letters of DEPT spectrum display Number, respectively 1 CH3(δ: 14.63), carbonyl carbon (δ: 175.48), 9 CH2(δ 21.48,25.98,26.52,28.15, 30.18,30.27,34.94,66.58,71.89), 7 CH, including 6 olefinic carbons (128.25,128.86,129.21,129.22, 131.09,132.74) and one fatty carbon (δ: 69.65), and monosaccharide 6 carbon signals (δ: 104.6,72.59,74.87, 70.30,76.78,62.50).1H-NMR spectrum one active H signal δ 4.53 (1H, bs) of display, shows to there may be an amino Group.
Sugar end group carbon coupling constant be 7.6Hz, between 6 to 8Hz, δ (104.6) between 103 to 105ppm, explanation β-Glucopyranose. group exists.HMBC spectrum relevant peaks display H-3 " to C-1 " relevant, H-6 " and C-4 " be correlated with show β-pyrans Glucose group on end group carbon and 6 β positions respectively by C-3 ", C-4 " disubstituted.And (δ C-3 " 71.89, δ C-4 " 69.65) Chemical shift is moved to low field.Additionally, H-3 " and H-4 " strong correlation explanation C-3 on 2D NMR ", C-4 " it is joined directly together, and And formed and the disubstituted octatomic ring of glucosyl group.Meanwhile, HMBC spectrum can be observed relevant peaks: H-2/C-1, C-3, C-4, C-5；H- 3/C-1, C-2, C-5；H-4/C-2, C-3, C-5；H-5/C-4, C-6；H-6/C-7, C-8；H-7/C-6；H-8/C-9；H-9/C- 7, C-8, C-10, C-11, C-12；H-10, H-12/C-9；H-14/C-11, C-12, C-13, C-15；H-15/C-13, C-14 with And the linear spin system H-2/H-3/H-4/H-5/H-6/H-8/H-9/H-10/H-11/H-12/H-13/H-in H-H COSY The existence of 14/H-15 one Long carbon chain of prompting.6 olefinic carbons signal that is relative to each other in NOE spectrum and H-H COSY spectrum is intensive, shows It forms the most neighbouring double bond, H-9 (δH2.81,2H, t, J=6Hz) deshield effect also illustrate that it is positioned at three double bonds Between.C-1 (δ 175.48) is positioned at low field, thus it is speculated that it is amide groups.And the HMBC coherent signal of H-1', H-2, H-3 and C-1 Illustrate that amide group is between C-1' and C-2.According to information above, it may be determined that this new alkaloids is said structure.
The present invention also provides for the extraction separation method of this alkaloid compound above-mentioned, concretely comprises the following steps.
Step 1: weigh Herba Portulacae and be dried medical material 80kg, using 50% alcohol reflux, 50% ethanol consumption is medical material 8～16 times, reflux, extract, twice, each 2h, decompression recycling ethanol, cool to room temperature, obtain medicinal liquid standby.
Step 2: by gained medicinal liquid in step 1, uses the method for static adsorption by AB-8 type macroporous resin, uses successively Water, 50%, 70% ethanol gradient elution, repeatedly extract after 70% alcohol elution concentrating under reduced pressure 3 times by ethyl acetate, second Acetoacetic ester is 1:1 (v:v) with the volume ratio of concentrated solution, and less than 40 DEG C recovered under reduced pressure ethyl acetate, to extractum, obtain acetic acid second Ester extract.
Step 3: acetic acid ethyl ester extract in step 2 is separated through polyamide column, employing alcohol-water (0/100,30/70, 50/50,70/30,90/10, v/v) gradient elution, 70% ethanolic moiety separates through silica gel column chromatography after being evaporated, and wherein silica gel is 200～300 mesh, successively with acetate-methanol (10:1,5:1,1:1, v:v) gradient elution, there are 10 positions (the most common Obtain 10 bottles, every bottle of 400mL), to detect through thin layer chromatography, colour developing, the 4～7 eluting positions merging colour developing (i.e. merge aobvious 4～17 bottles of color, discard 1～3 bottle and 8～10 bottles), less than 40 DEG C of 4～7 position after merging is evaporated to do, standby With.
Step 4: by the most pretreated for gains in step 3 Sephadex LH-20 (hydroxypropyl polydextran gel) place Reason, with methanol-water (80:20) isocratic elution, obtains 7 positions (i.e. eluting obtains 10 bottles, every bottle of 200mL), through thin layer chromatography Detecting, colour developing, merged respectively at 3,4 positions of colour developing, less than 50 DEG C are evaporated to do, standby.Described Sephadex The preprocessing process of LH-20 gel is that methanol soaked 24h, upper prop, is washed till without muddy in instillation water with methanol, then with initial flow Move and balance each other.
Step 5: the position pretreated ODS medium pressure column chromatography that respectively developed the color by gained in step 4 separates, wherein filler granularity It is 20～40 μm, with methanol-water (80:20, v/v) isocratic elution (pressurization, making flow velocity is 1mL/min, and temperature is room temperature), obtains Amide alkaloid compound.Normalization method measures purity 90～99%.The preprocessing process of described ODS is that methanol soaked 24h, Upper prop, is washed till without muddy in instillation water with methanol, then balances each other with initial flow.
The antiinflammatory action of amide alkaloid compound of the present invention.
1, main material.
1.1, medicine and reagent: experiment amide alkaloid compound used is prepared by said method, purity be 90～ 99%, precision weighs, and is diluted to solution needed for following each dosage group with DMSO.DMEM high glucose medium, the hyclone (U.S. Hyclone company)；Penicillin, streptomycin (Hangzhou Ilex purpurea Hassk.[I.chinensis Sims company)；LPS (Sigma Co., USA)；IL-6、TNF-α、PGE2 ELISA kit (Cayman company of the U.S.)；Cell pyrolysis liquid, Griess reagent (green skies Bioisystech Co., Ltd).
1.2 cell strains: RAW264.7 macrophage (U.S.'s ATCC cell bank).
1.3 packets: be divided into matched group, LPS group and experimental group, each one group.
2 experimental techniques.
2.1 cells are cultivated, DMEM high glucose medium, add the hyclone of l0%, l% antibiotics (100U/mL penicillin With 100 μ g/mL streptomycins), it is placed in 37.5%, CO2Incubator is cultivated.
2.2MTT colorimetric method for determining cell viability, above-mentioned three groups of trophophase RAW264.7 macrophage inoculations of taking the logarithm respectively In 96 well culture plates, cell density is 1 × 104Individual/mL, every hole 100 μ L, temperature 37 DEG C, 5%CO2Under the conditions of overnight incubation After, experimental group adds new alkaloids compound oleraciamide C (1-50 μM) of the present invention of variable concentrations, hatches 1h backward LPS group and experimental group are separately added into the LPS of final concentration of 1 μ g/mL, separately set zeroing group (containing the culture fluid of DMSO solvent), often group If 3 multiple holes, investigate the impact added after medicine cell.After above-mentioned each group of cell cultivates 24h, add in each porocyte 5mg/mL MTT 20 μ L, temperature 37 DEG C, 5%CO2Under the conditions of continue to hatch 4h after, terminate cultivate, inhale abandon liquid in hole, every hole Adding 100 μ L dimethyl sulfoxide (DMSO), vibrate 10min, makes intracellular crystallization fully dissolve, and surveys at microplate reader 570nm wavelength Fixed each hole light absorption value.
2.3 utilize Ge Lisi (Griess) method to measure the content of NO, investigate new alkaloids compound of the present invention and induce LPS The inhibitory action of NO generation amount of mouse macrophage RAW264.7.Mouse macrophage RAW264.7 pass on after containing 10% Cultivating in the high sugar cell culture medium DMEM of hyclone, experimental group adds the new alkaloids compound of the present invention of variable concentrations Oleraciamide C (1-20 μM), at 37 DEG C, 5%CO2Under the conditions of hatch after 1h by LPS (final concentration of 1 μ g/mL) induction inflammation Disease is reacted, and collects supernatant after 24h, and often group processes and repeats 3 holes.Griess method measures the content of NO in cell supernatant, according to The impact of the RAW264.7 cell release NO that LPS is induced by variable concentrations new alkaloids of the present invention compound, in order to reflect NO water Flat.
2.4ELISA method measures inflammatory factor IL-6, TNF-α and inflammatory mediator PGE2: by huge for exponential phase RAW264.7 Phagocyte is inoculated in 24 well culture plates, and cell density is 1 × 105Individual/mL, every hole 1mL, temperature 37 DEG C, 5%CO2Under the conditions of train Supporting overnight, experimental group adds new alkaloids compound oleraciamide C (1-20 μM) of the present invention, after cultivating 1h, adds in every hole Entering LPS (final concentration of 1 μ g/mL), hatch 24h altogether, often group processes and repeats 3 holes.ELISA method measures Herba Portulacae source new alkaloids The IL-6 of RAW264.7 macrophages secrete, TNF-α and PGE after process2Content.
3 experimental results.
Test result indicate that the macrophage RAW264.7's that LPS induces by the present invention special amide alkaloid compound Propagation is without impact, safety non-toxic；And the macrophage RAW264.7 that can effectively suppress LPS to induce produced excess inflammatory cell because of Sub-IL-6, TNF-α and inflammatory mediator NO, PGE2, and in concentration dependant.
Comparative survival rate of cells experimental result is as shown in table 2.
Table 2: the present invention impact on RAW264.7 macrophage relative survival rate.
Note:*P < 0.05 compares (high concentration group has significant difference) with matched group.
The content experimental result utilizing Ge Lisi (Griess) method to measure NO is shown in Table 3.
Table 3: the impact (mean ± standard deviation, n=3) of the RAW264.7 cell release NO that LPS is induced by the present invention.
Note:*P < 0.05 compares with matched group,#P < 0.05 and LPS group compares.
ELISA method measures inflammatory factor IL-6, TNF-α and inflammatory mediator PGE2Result is as shown in table 4.
Table 4: the IL-6 of RAW264.7 emiocytosis, TNF-α and the PGE that LPS is induced by the present invention2The impact of content is (all Number ± standard deviation, n=3).
Note:*P < 0.05 compares with matched group,#P < 0.05 and LPS group compares.
The antitumor action of amide alkaloid compound of the present invention.
1 main material.
1.1 medicines and reagent: experiment amide alkaloid compound used is prepared by said method, purity be 90～ 99%, precision weighs, and is diluted to solution needed for following each dosage group with DMSO.DMEM high glucose medium, the hyclone (U.S. Hyclone company)；Penicillin, streptomycin (Hangzhou Ilex purpurea Hassk.[I.chinensis Sims company).
1.2 cell strains: Human colon adenocarcinoma cell line Caco-2, human breast cancer cell line Bcap-37, human gastric cancer cells BGC-823, people's lung Adenocarcinoma cell SPC-A1, human liver cancer cell BEL-7402, human cervical carcinoma cell Hela-229, ovarian cancer cell Ho-8910, the mankind Oral cavity epidermoid carcinoma cell KB (above cell derives from Chinese Academy of Sciences's Shanghai cell bank).
1.3 packets: be divided into matched group, experimental group and zeroing group (containing the culture fluid of DMSO solvent).
2 experimental techniques.
2.1 cells are cultivated, DMEM high glucose medium, add the hyclone of l0%, l% antibiotics (100U/mL penicillin With 100 μ g/mL streptomycins), it is placed in 37 DEG C, 5%CO2Incubator is cultivated.
2.2MTI method detection cell proliferation, trophophase cell of taking the logarithm is inoculated in 96 well culture plates, and cell density is 1 × 104Individual/mL, every hole 100 μ L, temperature 37 DEG C, 5%CO2Under the conditions of after overnight incubation, experimental group adds the present invention of variable concentrations New alkaloids compound, often group sets 3 multiple holes, and dosing is placed on 37 DEG C, 5%CO2Incubator is cultivated 48h.Pastille is cultivated Liquid sucks, and adds serum-free medium and MTT (whole mass concentration is 5mg/mL) 100mL altogether that volume ratio is 4:1, continues to hatch 4h, after carefully sucking supernatant, every hole adds DMSO 150 μ L, is put on oscillator concussion so that crystallization is completely dissolved (5min), microplate reader detects absorbance (A) value in each hole under 570nm wavelength.Then, each concentration compound on intracellular is calculated raw Long suppression ratio, suppression ratio formula: inhibitory rate of cell growth=(1-AMedicine feeding hole/AControl wells) × 100%, reapplies SPSS software processes Data, make curve by suppression ratio to drug level, calculate IC50Value.
3 experimental results.
Test result indicate that amide alkaloid compound of the present invention is to Human colon adenocarcinoma cell line Caco-2, human breast cancer cell MCF-7, human gastric cancer cells BGC-823, human lung adenocarcinoma cell SPC-A1, human liver cancer cell BEL-7402, human cervical carcinoma cell Hela-229, ovarian cancer cell Ho-8910, Human Oral Cavity epidermoid carcinoma cell KB, propagation inhibited, and with medicine Concentration increases, and suppression ratio is the most significantly raised, i.e. in concentration dependant.Noval chemical compound of the present invention is to above-mentioned eight kinds of tumor cell IC50Value It is shown in Table 5.
The table 5 noval chemical compound of the present invention inhibitory action to tumor cell.
The neuroprotective of amide alkaloid compound of the present invention.
1 main material.
1.1 medicines and reagent: experiment new alkaloids compound used is prepared by said method, and purity is 90～99%, essence Close weigh, be diluted to solution needed for following each dosage group with DMSO.(U.S. Hyclone is public for DMEM high glucose medium, hyclone Department)；Penicillin, streptomycin (Hangzhou Ilex purpurea Hassk.[I.chinensis Sims company), phosphate buffer (PBS), (Wuhan doctor's moral company limited), ROS Detection kit (the green skies, Haimen Reagent Company).
1.2 cell strains: human neuroblastoma cells's strain (SH-SY5Y, IMR-32) (Chinese Academy of Sciences's Shanghai cell.
1.3 packet: be divided into matched group, H2O2Damage model group and experimental group.
2 experimental techniques.
2.1 cells are cultivated, DMEM high glucose medium, add the hyclone of l0%, l% antibiotics (100U/mL penicillin With 100 μ g/mL streptomycins), it is placed in 37 DEG C, 5%CO2 incubator is cultivated.
2.2MTT colorimetric method for determining cell viability, above-mentioned three groups of take the logarithm respectively trophophase SH-SY5Y cell and IMR-32 Cell is inoculated in 96 well culture plates, and cell density is 1 × 104Individual/mL, every hole 100 μ L, temperature 37 DEG C, under the conditions of 5%CO2 After overnight incubation, experimental group adds amide alkaloid compound oleraciamide C (the 5-40 μ of the present invention of variable concentrations M), hatch after 1h to H2O2Group and experimental group are separately added into the H of final concentration of 800 μMs/L2O2, separately set zeroing group (containing DMSO solvent Culture fluid, during microplate reader detection zeroing with), often group sets 3 multiple holes, investigates the impact added after medicine cell.Above-mentioned respectively After group cell cultivates 24h, each porocyte adds 5mg/mL MTT 20 μ L, temperature 37 DEG C, 5%CO2Under the conditions of continue to hatch After 4h, terminating cultivating, inhale and abandon liquid in hole, every hole adds 100 μ L dimethyl sulfoxide (DMSO), and vibrate 10min, makes intracellular knot Brilliant fully dissolving, mensuration each hole light absorption value (A) value at microplate reader 450nm wavelength, calculating cell survival rate, cell survival rate= (AH2O2Damage-A is blank)/(A comparison-A is blank).
2.3DCFH-DA method detection SH-SY5Y cell and the intracellular ROS of IMR-32, each group cell is incubated after giving respective substance Educating 24h, hatch 30min before end, each hole adds DCFH-DA, makes final concentration of 10 μm ol/L, continues to hatch 30min in 37 DEG C, Collecting cell, PBS washes 2 times, and each group of cell is made the cell suspension of same concentrations by cell counting.Take 100 μ L cell suspension inspections Survey fluorescence intensity, excitation wavelength 485nm, launch wavelength 538nm.With matched group fluorescence intensity for 100%, remaining is respectively organized and compares Group fluorescence intensity compares, and calculates the change of intracellular ROS.
2.4INT chromogenic reaction method measures the burst size of LDH, except above-mentioned matched group, H2O2Outside damage model group and experimental group, Separately setting up blank group (blank group not inoculating cell), each group cell adds respective substance and cultivates 24h, takes each hole supernatant 120 μ L in 96 new orifice plates, add the LDH that 60 μ L prepare and detect working solution, lucifuge incubated at room 30min, and 490nm at, use is many Function microplate reader measures A value, calculates the LDH burst size percentage rate relative to control tube.LDH release rate=(it is empty that A is administered-A In vain)/(A comparison-A is blank).
3 experimental results.
Comparative survival rate of cells experimental result is as shown in table 6.
Table 6: the present invention is on human neuroblastoma cells strain SH-SY5Y and the impact of IMR-32 comparative survival rate of cells.
Note:*P < 0.05 and H2O2Damage model group compares.
SH-SY5Y cell and IMR-32 intracellular ROS amount testing result are as shown in table 7.
Table 7: the impact that the human neuroblastoma cells intracellular ROS of strain SH-SY5Y and IMR-32 is measured by the present invention.
Note:*P < 0.05 compares with matched group,#P < 0.05 and H2O2Damage model group compares.
It is as shown in table 8 that what SH-SY5Y cell and the intracellular LDH of IMR-32 discharged affects result.
Table 8: the impact that the human neuroblastoma cells intracellular LDH of strain SH-SY5Y and IMR-32 is discharged by the present invention.
Note:*P < 0.05 compares with matched group,#P < 0.05 and H2O2Damage model group compares.
In sum, the present invention provides special amide alkaloid compound and extraction separation method thereof, uses successively The extraction of 50% alcohol reflux, macroporous adsorption resin chromatography, ethyl acetate, polyamide column chromatography, silica gel column chromatography, In Sephadex LH-20 purification, ODS, compression leg is isolated and purified, a kind of special amide-type new alkaloids chemical combination of successful isolated Thing, the method is easy, quickly, environmental protection, and higher through the compound purity of the method isolated, due to gained compound chemistry Structure is unique, extracts from conventional Chinese medicine Herba Portulacae, and it has antiinflammatory, antitumor and a neuroprotective, therefore this Bright special amide alkaloid and salt and derivant thereof can develop new Chinese medicine as natural product, have broad prospects.

Claims (7)

1. amide alkaloid compound in a Herba Portulacae, it is characterised in that molecular formula is C24H39O7, named Oleraciamide C, chemical structural formula is as follows.
2. compound as claimed in claim 1, it is characterised in that concretely comprise the following steps:
Step 1, take Herba Portulacae and be dried medical material, use 50% alcohol reflux, decompression recycling ethanol, cool to room temperature, obtain medicine Liquid is standby.
Step 2, concentrated solution in step 1 uses the method for static adsorption by AB-8 type macroporous resin, uses water successively, 50%, 70% ethanol gradient elution, by 70% alcohol elution, repeatedly extract with acetic acid after concentrating under reduced pressure, recovered under reduced pressure second Acid, to extractum, obtains acetic acid ethyl ester extract.
Step 3, by acetic acid ethyl ester extract in step 2 through polyamide column separate, use alcohol-water gradient elution, 70% ethanol Part is upper silicagel column after being evaporated, and obtains some eluting positions with acetate-methanol gradient elution successively, carries out through thin layer chromatography Detection, colour developing, merge the eluting position of colour developing, the eluting position after merging is done through being evaporated to, standby.
Step 4, by gains in step 2 again through Sephadex LH-20 (hydroxypropyl polydextran gel) process, with methanol-water etc. Degree eluting, obtains some eluting positions, detects through thin layer chromatography, and colour developing merges the eluting position of colour developing, after merging Eluting position is done through being evaporated to, standby.
Step 5, by gained concentrate pretreated ODS post in step 4 (Octadecylsilyl, octadecylsilane be bonded Silica filler) chromatography, the amide alkaloid compound deriving from Herba Portulacae is afforded with methanol-water.
3. extraction separation method as claimed in claim 1, it is characterised in that 50% alcohol reflux two in described step 1 Secondary, backflow 2 hours every time, amount of alcohol is 8～16 times of medical material.
4. extraction separation method as claimed in claim 1, it is characterised in that described ODS and Sephadex LH-20 gel Preprocessing process is that methanol soaked 24 hours, upper prop, is washed till in instillation water without muddy more equal with initial flow with methanol Weighing apparatus.
5. extraction separation method as claimed in claim 2, it is characterised in that in described step 2, concentrated solution ethyl acetate extracts Taking 3 times, ethyl acetate is 1:1 with the weight ratio of concentrated solution.
6. extraction separation method as claimed in claim 2, it is characterised in that flowing phase elution program used in described step 1 For isocratic elution.
7. compound as claimed in claim 1, it is characterised in that may be used for preparing antiinflammatory, antitumor and neuroprotective Medicine or health product.
CN201610663629.3A 2016-08-15 2016-08-15 Amide alkaloid compound and its extraction separation method in purslane Active CN106279305B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610663629.3A CN106279305B (en) 2016-08-15 2016-08-15 Amide alkaloid compound and its extraction separation method in purslane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610663629.3A CN106279305B (en) 2016-08-15 2016-08-15 Amide alkaloid compound and its extraction separation method in purslane

Publications (2)

Publication Number Publication Date
CN106279305A true CN106279305A (en) 2017-01-04
CN106279305B CN106279305B (en) 2018-07-27

Family

ID=57669936

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610663629.3A Active CN106279305B (en) 2016-08-15 2016-08-15 Amide alkaloid compound and its extraction separation method in purslane

Country Status (1)

Country Link
CN (1) CN106279305B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108084060A (en) * 2017-12-07 2018-05-29 辽宁中医药大学 Alkaloid oleraurea and its extraction separation method in purslane
CN108542926A (en) * 2018-05-23 2018-09-18 广东工业大学 The preparation method and pharmaceutical composition of a kind of purslane extract and its application
CN109897077A (en) * 2019-04-03 2019-06-18 辽宁中医药大学 Compound Oleraciamide E and its extraction separation method and application in purslane

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101234121A (en) * 2008-03-05 2008-08-06 山东大学 Application of purslane amide alkaloid in preparing antioxidant and neuroprotective agent
CN102973619A (en) * 2012-12-31 2013-03-20 山东大学 Process for extracting indoline amide alkaloid from purslane and detection methods for indoline amide alkaloid
CN105085534A (en) * 2014-12-22 2015-11-25 辽宁中医药大学 Novel skeleton alkaloid compound and extraction separation method thereof
CN105232539A (en) * 2015-10-16 2016-01-13 辽宁中医药大学 Application of two purslane-derived alkaloids to preparation of anti-inflammatory medicines or healthcare products
CN105330588A (en) * 2015-10-16 2016-02-17 辽宁中医药大学 Novel alkaloid Oleracone in herba portulacae, and extraction separation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101234121A (en) * 2008-03-05 2008-08-06 山东大学 Application of purslane amide alkaloid in preparing antioxidant and neuroprotective agent
CN102973619A (en) * 2012-12-31 2013-03-20 山东大学 Process for extracting indoline amide alkaloid from purslane and detection methods for indoline amide alkaloid
CN105085534A (en) * 2014-12-22 2015-11-25 辽宁中医药大学 Novel skeleton alkaloid compound and extraction separation method thereof
CN105232539A (en) * 2015-10-16 2016-01-13 辽宁中医药大学 Application of two purslane-derived alkaloids to preparation of anti-inflammatory medicines or healthcare products
CN105330588A (en) * 2015-10-16 2016-02-17 辽宁中医药大学 Novel alkaloid Oleracone in herba portulacae, and extraction separation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
K. CHAN，ET AL.: ""The analgesic and anti-in¯ammatory effects of Portulaca oleracea L. subsp. sati6a (Haw.) Celak"", 《JOURNAL OF ETHNOPHARMACOLOGY》 *
丁怀伟，等: ""马齿苋的化学成分和药理活性研究进展"", 《沈阳药科大学学报》 *
杨子娟，等: ""马齿苋的化学成分研究"", 《中药材》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108084060A (en) * 2017-12-07 2018-05-29 辽宁中医药大学 Alkaloid oleraurea and its extraction separation method in purslane
CN108084060B (en) * 2017-12-07 2020-04-21 辽宁中医药大学 Alkaloid oleraurea in purslane and extraction and separation method thereof
CN108542926A (en) * 2018-05-23 2018-09-18 广东工业大学 The preparation method and pharmaceutical composition of a kind of purslane extract and its application
CN109897077A (en) * 2019-04-03 2019-06-18 辽宁中医药大学 Compound Oleraciamide E and its extraction separation method and application in purslane
CN109897077B (en) * 2019-04-03 2021-07-30 辽宁中医药大学 Compound Oleraceamide E in purslane, and extraction separation method and application thereof

Also Published As

Publication number Publication date
CN106279305B (en) 2018-07-27

Similar Documents

Publication Publication Date Title
CN106946766B (en) Alkaloid compound and its extraction separation method in purslane
CN109897077B (en) Compound Oleraceamide E in purslane, and extraction separation method and application thereof
CN109824568B (en) Two indole novel alkaloid compounds in purslane and extraction and separation method and application thereof
CN107459477B (en) Isoindole alkaloid compound in purslane and extraction and separation method thereof
CN107746397B (en) Compound Oleracone C and its extraction separation method in purslane
CN107698546B (en) Compound Oleracone D and its extraction separation method in purslane
CN110272342B (en) Naphthoic acid compound in purslane and extraction and separation method and application thereof
CN108084060B (en) Alkaloid oleraurea in purslane and extraction and separation method thereof
CN108558809A (en) Compound Oleracone F and its extraction separation method in purslane
CN106008502A (en) Alkaloid compounds with novel skeletons in purslane and extraction and separation method thereof
CN111217773B (en) Furan ring compound in purslane and extraction and separation method and application thereof
CN111303154B (en) Alkaloid with anti-inflammatory activity in purslane, and extraction and separation method and application thereof
CN110305084B (en) Nitrogen-containing organic acid compound in purslane, extraction and separation method and application thereof
CN108864004A (en) The purposes of the rich volt lactone of hydroxyl dihydro and its derivative in purslane
CN106279305B (en) Amide alkaloid compound and its extraction separation method in purslane
CN107827726A (en) Compound Oleracone E and its extraction separation method in purslane
CN109336747A (en) Oleralignan and its extraction separation method and its application in purslane
CN109942481B (en) Compound Oleraisoindole A in purslane, and extraction separation method and application thereof
CN106083556B (en) Azulene structural compounds and its extraction separation method in purslane
CN106220587B (en) Two kinds of alkaloid compounds and its extraction separation method in purslane
CN106810551A (en) Two kinds of new carbon skeleton alkaloid compounds and its extraction separation method
CN110305094B (en) Two flavonoid compounds in purslane and extraction and separation method and application thereof
CN114989064A (en) Novel pyrrole alkaloid compound in purslane and extraction and separation method thereof
CN110294733B (en) Peroxide bond-containing compound Oleracone I in purslane, and extraction separation method and application thereof
CN110256326B (en) Indoline carboxylic acid alkaloid in purslane and extraction and separation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant